Response to Comments: Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers

This article responds to public comments about coverage of skin substitute grafts and cellular and tissue‑based products (CTPs) for diabetic foot ulcers and venous leg ulcers, clarifying interpretation of existing Medicare contractor policies rather than announcing new blanket inclusions or exclusions. It reiterates key requirements: medical‑necessity documentation, adherence to product‑specific indications and evidence thresholds, and any applicable prior‑authorization and billing/documentation rules.